Abstract
Aims
A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).
Materials and methods
In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.
Key findings
The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.
Significance
The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.
【저자키워드】 COVID-19, docking, sofosbuvir, RdRP, structural bioinformatics, Wuhan coronavirus, Nucleotide inhibitors, 【초록키워드】 viral infection, Human, Transmission, drug, in silico, MERS, RNA, China, Wuhan, Sequence analysis, Effectiveness, death, WHO, RNA polymerase, disease, deaths, Efficiency, World Health Organization, confirmed case, approved drug, Anti-HCV, material, IDX-184, Wuhan, China, human coronavirus, responsible, reported, anti-polymerase drugs, build, Significance, 【제목키워드】 inhibitors, nucleotide,